Lipogenesis in arterial wall and vascular smooth muscular cells: Regulation and abnormalities in insulin-resistance

Cardiovascular Diabetology

Volumn 8, Issue , 2009, Pages

  Hamlat, Nadjiba ^a   Forcheron, Fabien ^a   Negazzi, Samia ^b   del Carmine, Peggy ^a   Feugier, Patrick ^a,c   Bricca, Giampiero ^a   Aouichat Bouguerra, Souhila ^b   Beylot, Michel ^a  

^a UNIVERSITÉ LYON 1   (France)

^b UNIVERSITY OF SCIENCES AND TECHNOLOGY HOUARI BOUMEDIENE   (Algeria)

^c HOSPICES CIVILS DE LYON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; METFORMIN; SULFONYLUREA; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; FLUORINATED HYDROCARBON; GLUCOSE; INSULIN; LIVER X RECEPTOR; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; ORPHAN NUCLEAR RECEPTOR; SULFONAMIDE; TO-901317;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY WALL; ARTICLE; ATHEROMA; CAROTID ENDARTERECTOMY; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FAT CONTENT; FATTY ACID SYNTHESIS; FATTY ACID TRANSPORT; FEMALE; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; LIPOGENESIS; MALE; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR SMOOTH MUSCLE; ANIMAL; AORTA; ATHEROSCLEROSIS; CAROTID ARTERY; CELL CULTURE; CULTURE MEDIUM; DISEASE MODEL; DRUG EFFECT; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; SMOOTH MUSCLE FIBER; TIME; ZUCKER RAT;

AGED; ANIMALS; AORTA; ATHEROSCLEROSIS; CAROTID ARTERIES; CELLS, CULTURED; CULTURE MEDIA; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE; HUMANS; HYDROCARBONS, FLUORINATED; INSULIN; INSULIN RESISTANCE; LIPOGENESIS; MALE; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OBESITY; ORPHAN NUCLEAR RECEPTORS; RATS; RATS, ZUCKER; RNA, MESSENGER; SULFONAMIDES; TIME FACTORS; TRIGLYCERIDES;

EID: 74549219334     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-8-64     Document Type: Article

References (55)

1. Schaffer J. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003, 14:281-287. 10.1097/00041433-200306000-00008, 12840659.
2. Schulman G. Cellular mechanisms of insulin resistance. J Clin Invest 2000, 106:171-176. 10.1172/JCI10583, 314317, 10903330.
3. Capeau J. Insulin resistance and steatosis in humans. Diabetes Metab 2008, 34:649-657. 10.1016/S1262-3636(08)74600-7, 19195626.
4. Schrauwen P. High-fat diet, muscular lipotoxicity and insulin resistance. Proc Nutr Soc 2007, 66:33-41. 10.1017/S0029665107005277, 17343770.
5. Listenberger L, Han X, Lewis S, Cases S, Farese R, Ory D, Schaffer J. Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci 2003, 100:3077-3082. 10.1073/pnas.0630588100, 152249, 12629214.
6. Yu CCY, Cline GW, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI. Mechanism by Which Fatty Acids Inhibit Insulin Activation of Insulin Receptor Substrate-1 (IRS-1)-associated Phosphatidylinositol 3-Kinase Activity in Muscle. J Biol Chem 2002, 277:50230-50236. 10.1074/jbc.M200958200, 12006582.
7. Park T, Hu Y, Noh H, Drosatos K, Okajima K, Buchanan J, Tuinei J, Homma S, Jiang X, Abel E, et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J Lipid Res 2008, 49:2101-2112. 10.1194/jlr.M800147-JLR200, 2533410, 18515784.
8. Haus J, Kashyap S, Kasumov T, Zhang R, Kelly K, De Fronzo R, Kirwan J. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 2009, 58:337-344. 10.2337/db08-1228, 19008343.
9. Jiang Z, Lin Y, Clemont A, Feener E, Hein K, Igarashi M, Yamauchi T, White M, King G. Characterization of the selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 1999, 104:447-457. 10.1172/JCI5971, 408521, 10449437.
10. Hodroj W, Legedz L, Foudi N, Cerutti C, Bourdillon M, Feugier P, Beylot M, Randon J, Bricca G. Increased Insulin-Stimulated Expression of Arterial Angiotensinogen and Angiotensin Type 1 Receptor in Patients With Type 2 Diabetes Mellitus and Atheroma. Arterioscler Thromb Vasc Biol 2007, 27:525-531. 10.1161/01.ATV.0000254814.63768.3b, 17170378.
11. Hotamisligil G, Budavari A, Murray D, Spielgelman B. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Contral role of TNF alpha. J Clin Invest 1994, 94:1543-1549. 10.1172/JCI117495, 295304, 7523453.
12. Folli F, Kahn C, Hansen H, Bouchie J, Feener E. Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 1997, 100:2158-2169. 10.1172/JCI119752, 508410, 9410892.
13. Davies J, Carpenter K, Challis I, Figg N, McNair R, Proudfoot D, Weissberg P, Shanahan C. Adipocytic differenciation and liver × receptor pathways regulate the accumulation of triacylglycerols in human vascular smooth muscle cells. J Biol Chem 2005, 280:3911-3919. 10.1074/jbc.M410075200, 15548517.
14. Smith E, Slate E, Chu P. The lipids in raised fatty and fibrous lesions in human aorta. A comparison of the changes at different stage of development. J Atheroscler Res 1968, 8:399-419. 10.1016/S0368-1319(68)80097-3, 5660505.
15. Smith E, Slater R. The microdissection of large atherosclerotic plaques to give morphologically and topographically defined fractions for analysis. 1. the lipids in isolated fractions. Atherosclerosis 1972, 15:37-56. 10.1016/0021-9150(72)90036-6, 5013277.
16. Lada AT, Rudel LL, Clair RWS. Effects of LDL enriched with different dietary fatty acids on cholesteryl ester accumulation and turnover in THP-1 macrophages. Journal of Lipid Research 2003, 44(4):770-779. 10.1194/jlr.M200431-JLR200, 12562836.
17. Adelman SJ, Glick JM, Phillips MC, Rothblat GH. Lipid composition and physical state effects on cellular cholesteryl ester clearance. Journal of Biological Chemistry 1984, 259(22):13844-13850.
18. Portman O. Arterial composition and metabolism: esterified fatty acids and cholesterol. Adv Lipid Res 1970, 8:41-114.
19. Foufelle F, Ferré P. New perspectives in the regulation of hepatic glycolytic and lipogenic genes by insulin and glucose: a role for the transcription factor sterol regulatory element binding protein-1c. Biochem J 2002, 366:377-391. 10.1042/BJ20020430, 1222807, 12061893.
20. Repa LG, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000, 14:2819-2830. 10.1101/gad.844900, 317055, 11090130.
21. Kase ET, Wensaas AJ, Aas V, Hojlund K, Levin K, Thoresen GH, Beck-Nielsen H, Rustan AC, Gaster M. Skeletal Muscle Lipid Accumulation in Type 2 Diabetes May Involve the Liver × Receptor Pathway. Diabetes 2005, 54(4):1108-1115. 10.2337/diabetes.54.4.1108, 15793250.
22. Juvet AS, Schuster GU, Dalen KT, Tobin KA, Hollung K, Haugen F, Jacinto S, Ulven SM, Bamberg K, Gustafsson JA, Nebb HI. On the role of liver × receptors in lipid accumulation in adipocytes. Mol Endocrinol 2003, 17:172-182. 10.1210/me.2001-0210, 12554745.
23. Cozzone D, Debard C, Dif N, Ricard N, Disse E, Vouillarmet J, Rabasa-Lhoret R, Laville M, Pruneau D, Rieusset J, et al. Activation of liver × receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 2006, 49(5):990-999. 10.1007/s00125-006-0140-8, 16482468.
24. Uyeda K, Yamashita H, Kawaguchi T. Carbohydrate responsive element-binding protein (ChREBP): a key regulator of glucose metabolism and fat storage. Biochemical Pharmacology 2002, 63:13476-13478.
25. Dentin R, Pegorier J, Benhamed F, Foufelle F, Ferré P, Fauveau V, Magnuson M, Girard J, Postic C. Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem 2004, 279:20314-20326. 10.1074/jbc.M312475200, 14985368.
26. Ducluzeau P-H, Perretti N, Laville M, Andreelli F, Vega N, Riou J-P, Vidal H. Regulation by Insulin of Gene Expression in Human Skeletal Muscle and Adipose Tissue: Evidence for Specific Defects in Type 2 Diabetes. Diabetes 2001, 50(5):1134-1142. 10.2337/diabetes.50.5.1134, 11334418.
27. Mitro N, Vargas L, Romeo R, Koder A, Saez E. T0901317 is a potent PXR ligand: Implications for the biology ascribed to LXR. FEBS Letters 2007, 581(9):1721-1726. 10.1016/j.febslet.2007.03.047, 17418145.
28. Moreau A, Téruel C, Beylot M, Albalea V, Tamasi V, Umbdenstock T, Parmentier Y, Sa-Cunha A, Suc B, Fabre J, et al. A novel pregnane × receptor and S14-mediated lipogenic pathway in human hepatocyte. Hepatology 2009, (49):2068-2079. 10.1002/hep.22907, 19437491.
29. Hagedorn KA, Cooke C-L, Falck JR, Mitchell BF, Davidge ST. Regulation of Vascular Tone During Pregnancy: A Novel Role for the Pregnane × Receptor. Hypertension 2007, 49(2):328-333. 10.1161/01.HYP.0000253478.51950.27, 17159084.
30. Forcheron F, Legedz L, Chinetti G, Feugier P, Letexier D, Bricca G, Beylot M. Genes of cholesterol metabolism in human atheroma: overexpression of perilipin and genes promoting cholesterol storage and repression of ABCA1 expression. Arterioscler Thromb Vasc Biol 2005, 25:1711-1717. 10.1161/01.ATV.0000174123.19103.52, 15961705.
31. Ran J, Hirano T, Adachi M. Chronic angiotensin II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol 2004, 287:E955-E961.
32. Jones B, Stanbridge M, Moustaid N. Angiotensin II increases lipogenesis in 3T3-L1 and human adipose cells. Endocrinology 1997, 138:1512-1519. 10.1210/en.138.4.1512, 9075710.
33. Bramlett KS, Houck KA, Borchert KM, Dowless MS, Kulanthaivel P, Zhang Y, Beyer TP, Schmidt R, Thomas JS, Michael LF, et al. A Natural Product Ligand of the Oxysterol Receptor, Liver × Receptor. Journal of Pharmacology And Experimental Therapeutics 2003, 307(1):291-296. 10.1124/jpet.103.052852, 12893846.
34. Forcheron F, Cachefo A, Thevenon S, Pinteur C, Beylot M. Mechanisms of the triglyceride and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients. Diabetes 2002, 51:3486-3491. 10.2337/diabetes.51.12.3486, 12453904.
35. Forcheron F, Abdallah P, Basset A, Del Carmine P, Haffar G, Beylot M. Non-Alcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate. Obesity 2009, 1381-1389.
36. Yang D, Diraison F, Beylot M, Brunengraber Z, Samols M, Brunengraber H. assay of low deuterium enrichment of water by isotopic exchange with [U-13C]acetone and gas chromatography mass spectrometry. Anal Biochem 1998, 258:315-321. 10.1006/abio.1998.2632, 9570847.
37. Diraison F, Pachiaudi C, Beylot M. Measuring lipogenesis and cholesterol synthesis in humans with deuterated water: use of simple gas chromatography mass spectrometry techniques. J Mass Spectrom 1997, 32:81-86. 10.1002/(SICI)1096-9888(199701)32:1<81::AID-JMS454>3.0.CO;2-2, 9008871.
38. Diraison F, Beylot M, Moulin P. Contribution of hepatic de novo lipogenesis and reesterification of plasma NEFA to plasma triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes & Metabolism 2003, 29:1-8.
39. Suh Y, Kim Y, Bang J, Choi K, Lee J, Kim W, Oh T, AN S, Jung M. Analysis of gene expression profiles in insulin-sensitive tissues from pre-diabetic and diabetic Zucker diabetic fatty rats. J Mol Endocrinol 2005, 34:299-315. 10.1677/jme.1.01679, 15821098.
40. Kakuma T, Lee Y, Higa M, Wanf Z, Pan W, Shimomura I, Unger R. Leptin, troglitazone, and the expression of sterol regulatory element binding proteins in liver and pancreatic islets. Proc Natl Aca Sci 2000, 97:8536-8541.
41. Cha JY, Repa JJ. The Liver × Receptor (LXR) and Hepatic Lipogenesis: the carbohydrate-response element binding protein is a target gene of LXR. J Biol Chem 2007, 282(1):743-751. 10.1074/jbc.M605023200, 17107947.
42. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, Billheimer J, Mukherjee R. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. Journal of Lipid Research 2004, 45(8):1410-1417. 10.1194/jlr.M300450-JLR200, 15145986.
43. Joseph SB, McKilligin E, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, et al. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proceedings of the National Academy of Sciences of the United States of America 2002, 99(11):7604-7609. 10.1073/pnas.112059299, 12032330.
44. Lin H, Yang S, Chuckabee C, Kuhajda F, Ronnet G, Dielh A. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nature Med 2000, 6:998-1003. 10.1038/79697, 10973319.
45. Laybutt D, SchmitzPeiffer C, Saha K, Ruderman N, Biden T, Kraegen E. Muscle lipid accumulation and protein kinase C activation in the insulin-resistant chronically glucose-infused rat. Am J Physiol 1999, 277:E1070-E1076.
46. Pan D, Lillioja S, Kriketos A, Milner M, Baur L, Bogardus C, Jenkins A, Storlien L. Skeletal muscle triglyceride levels are inversely related to insulin action. Diabetes 1997, 46:983-988. 10.2337/diabetes.46.6.983, 9166669.
47. Poitout V, Robertson RP. Glucolipotoxicity: Fuel Excess and beta-Cell Dysfunction. Endocrine Reviews 2008, 29(3):351-366. 10.1210/er.2007-0023, 2528858, 18048763.
48. Forcheron F, Basset A, Abdallah P, Del Carmine P, Gadot N, Beylot M. Diabetic cardiomyopathy: effects of fenofibrate and meformin in an experimental model - the Zucker diabetic rat. Cardiovascular Diabetology 2009, 8(1):16. 10.1186/1475-2840-8-16, 2664796, 19317897.
49. Zhou Y, Graybirn P, Karim A, Scimabukuro M, Higa M, Baetens D, Orci L, Unger R. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci 2000, 97:1784-1789. 10.1073/pnas.97.4.1784, 26513, 10677535.
50. Diraison F, Dusserre E, Vidal H, Sothier M, Beylot M. Increased hepatic lipogenesis but decreased expression of lipogenic gene in adipose tissue in human obesity. AmJ Physiol 2002, 282:E46-51.
51. Donnelly K, Smith C, Schwarzenberg S, Jessurun J, Boldt M, Parks E. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalocoholic fatty liver disease. J Clin Invest 2005, 115:1343-1351. 1087172, 15864352.
52. Denechaud DR, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. FEBS Lett 2008, 582:68-73. 10.1016/j.febslet.2007.07.084, 17716660.
53. Joseph ME, Pei L, Watson MA, Collins AR, Laffitte BA, Chen M, Noh G, Goodman J, Hagger GN, Tran J, Tippin TK, Wang X, Lusis AJ, Hsueh WA, Law RE, Collins JL, Willson TM, Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc Natl Acad Sci USA 2002, 99:7604-7609. 10.1073/pnas.112059299, 124297, 12032330.
54. Naik SU, Wang X, Da Silva JS, Jaye M, Macphee CH, Reilly MP, Billheimer JT, Rothblat GH, Rader DJ. Pharmacological Activation of Liver × Receptors Promotes Reverse Cholesterol Transport In Vivo. Circulation 2006, 113:90-97. 10.1161/CIRCULATIONAHA.105.560177, 16365197.
55. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 2008, 18:461-467. 10.1016/j.gde.2008.07.016, 2641014, 18782619.